GLPwatch
Papers (10401)
Page 33 of 174, ranked by citation count.
- Relationship between residual gastric content and peri-operative semaglutide use assessed by gastric ultrasound: a prospective observational study.
- Combined melatonin and exendin-4 therapy preserves renal ultrastructural integrity after ischemia-reperfusion injury in the male rat.
- Neuroprotective effects of liraglutide against inflammation through the AMPK/NF-κB pathway in a mouse model of Parkinson's disease.
- GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humans--PK/PD and safety.
- Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.
- Exendin-4 improved rat cortical neuron survival under oxygen/glucose deprivation through PKA pathway.
- Brain GLP-1 and insulin sensitivity.
- Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis.
- Coating of PLA-nanoparticles with cyclic, arginine-rich cell penetrating peptides enables oral delivery of liraglutide.
- Liraglutide ameliorates glycometabolism and insulin resistance through the upregulation of GLUT4 in diabetic KKAy mice.
- Glucose-responsive hydrogel enhances the preventive effect of insulin and liraglutide on diabetic nephropathy of rats.
- Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes.
- Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial.
- Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes.
- Glucagon-like Peptide-1 receptor agonist treatment patterns among type 2 diabetes patients in six European countries.
- The effect of fatty diacid acylation of human PYY<sub>3-36</sub> on Y<sub>2</sub> receptor potency and half-life in minipigs.
- Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.
- Shorter-acting glucagon-like peptide-1 receptor agonists are associated with increased development of gastro-oesophageal reflux disease and its complications in patients with type 2 diabetes mellitus: a population-level retrospective matched cohort study.
- Adults with early-onset type 2 diabetes (aged 18-39 years) are severely underrepresented in diabetes clinical research trials.
- Exendin-4 Reverses Biochemical and Functional Alterations in the Blood-Brain and Blood-CSF Barriers in Diabetic Rats.
- Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability.
- Attenuation of carotid neointimal formation after direct delivery of a recombinant adenovirus expressing glucagon-like peptide-1 in diabetic rats.
- Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial.
- Exenatide inhibits the growth of endometrial cancer Ishikawa xenografts in nude mice.
- Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.
- Patient preferences for glucagon-like peptide 1 receptor-agonist treatment attributes.
- LOX-1, a bridge between GLP-1R and mitochondrial ROS generation in human vascular smooth muscle cells.
- Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia.
- Effects of semaglutide on gut microbiota, cognitive function and inflammation in obese mice.
- Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects.
- A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes.
- Exendin-4 induces myocardial protection through MKK3 and Akt-1 in infarcted hearts.
- The Therapeutic Potential of GLP-1 Receptor Agonists in the Management of Hidradenitis Suppurativa: A Systematic Review of Anti-Inflammatory and Metabolic Effects.
- Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas.
- Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy).
- Normal pregnancy outcome after first-trimester exposure to liraglutide in a woman with Type 2 diabetes.
- The osteogenic effect of liraglutide involves enhanced mitochondrial biogenesis in osteoblasts.
- Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients With Type 2 Diabetes.
- Racial and Ethnic Disparities in Financial Barriers Among Overweight and Obese Adults Eligible for Semaglutide in the United States.
- Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges.
- 3-Iodothyronamine: a modulator of the hypothalamus-pancreas-thyroid axes in mice.
- Effects of exendin-4 alone and with peptide YY(3-36) on food intake and body weight in diet-induced obese rats.
- Improvement of psoriasis during exenatide treatment in a patient with diabetes.
- Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.
- The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF).
- The mTORC1/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice.
- DA5-CH and Semaglutide Protect against Neurodegeneration and Reduce <i>α</i>-Synuclein Levels in the 6-OHDA Parkinson's Disease Rat Model.
- Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial.
- Acute pancreatitis associated with liraglutide.
- Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients.
- Empagliflozin and Dulaglutide are Effective against Obesity-induced Airway Hyperresponsiveness and Fibrosis in A Murine Model.
- Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying--preclinical evidence.
- As Semaglutide's Popularity Soars, Rare but Serious Adverse Effects Are Emerging.
- Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.
- Updates on cardiovascular outcome trials in diabetes.
- Semaglutide once weekly in people with type 2 diabetes: Real-world analysis of the Canadian LMC diabetes registry (SPARE study).
- Exenatide for weight-loss maintenance in adolescents with severe obesity: A randomized, placebo-controlled trial.
- Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study.
- Glucagon-like peptide-1 receptor agonist, semaglutide attenuates chronic liver disease-induced skeletal muscle atrophy in diabetic mice.
- Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK.